RXC004 Phase 1 monotherapy data to be presented at ESMO Congress 2021

On September 13, 2021 Redx Pharma plc (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, reported that data from the Company’s RXC004 Phase 1 monotherapy study will be presented at the forthcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, 16-21 September 2021 (Press release, Redx Pharma, SEP 13, 2021, View Source [SID1234587580]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RXC004 is the Company’s lead drug candidate and is a potent, orally active porcupine inhibitor being developed as a targeted therapy for Wnt-ligand driven cancer. Based on the safety profile observed in the Phase 1 study, Redx has selected the 2mg dose of RXC004 for its planned Phase 2 monotherapy, proof of concept clinical trials which are expected to start during the second half of 2021.

The presentation at the ESMO (Free ESMO Whitepaper) Congress 2021 will be made by the Study Principal Investigator, Dr Natalie Cook, Consultant Medical Oncologist at the Christie Hospital NHS Trust, Manchester, UK.

Presentation No: 517MO
Authors: N Cook, S Blagden, J Lopez, D Sarker, A Greystoke, N Harris, F Kasmi, A Naderi, G Nintos, A Ortego Franco, R Pihlak, R Shinde, L Goodwin, C Phillips, J Robertson, A Saunders, C Tilston, S Woodcock, R Plummer
Title: Phase 1 study of the Porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours
Day/Date: Monday 20 September 2021
Presentation Time: 17:50pm to 17:55pm (CET)
Session Channel: Channel 3
Session Title: Developmental therapeutics
Session Type: Mini oral session
Session Time: 17:30pm to 18:30pm (CET)

Redx to host R&D Event
Presented data will be discussed by Medical Experts during Redx’s online R&D Event to be held on Monday 11 October 2021 at 1:00pm BST / 8.00am EDT. The event will also cover the Company’s pipeline beyond RXC004.